Skip to main content

CORRECTION article

Front. Med., 21 July 2023
Sec. Pulmonary Medicine
Volume 10 - 2023 | https://doi.org/10.3389/fmed.2023.1236279

Corrigendum: Serum CYR61 is associated with airway inflammation and is a potential biomarker for severity in chronic obstructive pulmonary disease

This article is a correction to:

  1. Serum CYR61 Is Associated With Airway Inflammation and Is a Potential Biomarker for Severity in Chronic Obstructive Pulmonary Disease

    1. Read original article
\r\nZhu-Xia Tan,&#x;Zhu-Xia Tan1,2†Lin Fu&#x;Lin Fu2†Wen-Jing WangWen-Jing Wang2Ping ZhanPing Zhan2Hui ZhaoHui Zhao2Hua Wang Hua Wang1*De-Xiang Xu De-Xiang Xu1*
  • 1Department of Toxicology, Anhui Medical University, Hefei, China
  • 2Second Affiliated Hospital, Anhui Medical University, Hefei, China

A corrigendum on
Serum CYR61 is associated with airway inflammation and is a potential biomarker for severity in chronic obstructive pulmonary disease

by Tan, Z.-X., Fu, L., Wang, W.-J., Zhan, P., Zhao, H., Wang, H., and Xu, D.-X. (2021). Front. Med. 8:781596. doi: 10.3389/fmed.2021.781596

In the published article, there was an error in affiliation. The affiliations were listed in the incorrect order. They should appear as:

1 Department of Toxicology, Anhui Medical University, Hefei, China

2 Second Affiliated Hospital, Anhui Medical University, Hefei, China

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: CYR61, COPD, NF-κB, lung function, inflammatory cytokines

Citation: Tan Z-X, Fu L, Wang W-J, Zhan P, Zhao H, Wang H and Xu D-X (2023) Corrigendum: Serum CYR61 is associated with airway inflammation and is a potential biomarker for severity in chronic obstructive pulmonary disease. Front. Med. 10:1236279. doi: 10.3389/fmed.2023.1236279

Received: 07 June 2023; Accepted: 08 June 2023;
Published: 21 July 2023.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2023 Tan, Fu, Wang, Zhan, Zhao, Wang and Xu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: De-Xiang Xu, eHVkZXgmI3gwMDA0MDsxMjYuY29t; Hua Wang, d2FuZ2h1YWRldiYjeDAwMDQwOzEyNi5jb20=

†These authors have contributed equally to this work

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.